Compare Stocks: RNAC, CVAC, OLMA, and SANA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
OLMA Olema Pharmaceuticals	$10.77 +1.3%	$11.26	$5.34 ▼ $36.26	$930.10M	2.03	960,416 shs	889,851 shs
RNAC Cartesian Therapeutics	$9.18 +3.8%	$8.88	$5.60 ▼ $11.80	$267.45M	0.63	114,569 shs	108,702 shs
SANA Sana Biotechnology	$3.68 +3.7%	$3.39	$2.61 ▼ $6.55	$1.06B	2.16	2.44 million shs	1.67 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-14.96%
OLMA Olema Pharmaceuticals	0.00%	-11.78%	-7.32%	-17.60%	+92.92%
RNAC Cartesian Therapeutics	0.00%	-0.11%	+7.02%	+28.30%	-21.98%
SANA Sana Biotechnology	0.00%	+0.85%	+12.70%	+16.78%	+6.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
OLMA Olema Pharmaceuticals	$10.77 +1.3%	$11.26	$5.34 ▼ $36.26	$930.10M	2.03	960,416 shs	889,851 shs
RNAC Cartesian Therapeutics	$9.18 +3.8%	$8.88	$5.60 ▼ $11.80	$267.45M	0.63	114,569 shs	108,702 shs
SANA Sana Biotechnology	$3.68 +3.7%	$3.39	$2.61 ▼ $6.55	$1.06B	2.16	2.44 million shs	1.67 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-14.96%
OLMA Olema Pharmaceuticals	0.00%	-11.78%	-7.32%	-17.60%	+92.92%
RNAC Cartesian Therapeutics	0.00%	-0.11%	+7.02%	+28.30%	-21.98%
SANA Sana Biotechnology	0.00%	+0.85%	+12.70%	+16.78%	+6.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
OLMA Olema Pharmaceuticals	2.71	Moderate Buy	$42.40	293.69% Upside
RNAC Cartesian Therapeutics	2.57	Moderate Buy	$32.60	255.12% Upside
SANA Sana Biotechnology	2.67	Moderate Buy	$9.33	153.62% Upside

Current Analyst Ratings Breakdown

Latest RNAC, CVAC, OLMA, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	SANA Sana Biotechnology	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00
8/3/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/23/2026	SANA Sana Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/30/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/12/2026	RNAC Cartesian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/10/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A
RNAC Cartesian Therapeutics	$1.48M	188.04	N/A	N/A	($4.85) per share	-1.89
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	N/A
RNAC Cartesian Therapeutics	-$130.30M	-$5.94	N/A	N/A	N/A	-8,550.65%	N/A	-29.84%	11/5/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)

Latest RNAC, CVAC, OLMA, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	RNAC Cartesian Therapeutics	-$0.8779	$0.46	+$1.3379	$0.46	$0.18 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
RNAC Cartesian Therapeutics	N/A	7.48	7.48
SANA Sana Biotechnology	N/A	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
OLMA Olema Pharmaceuticals	91.78%
RNAC Cartesian Therapeutics	86.95%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
OLMA Olema Pharmaceuticals	12.56%
RNAC Cartesian Therapeutics	37.20%
SANA Sana Biotechnology	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
OLMA Olema Pharmaceuticals	70	87.50 million	76.51 million	Optionable
RNAC Cartesian Therapeutics	64	30.26 million	19.00 million	Optionable
SANA Sana Biotechnology	380	299.36 million	223.32 million	Optionable

RNAC, CVAC, OLMA, and SANA Headlines

Recent News About These Companies

Bank of America Cuts Sana Biotechnology (NASDAQ:SANA) Price Target to $6.00

August 17 at 2:01 AM | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% After Analyst Downgrade

August 16 at 4:21 AM | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter?

August 15 at 4:22 PM | kalkinemedia.comK

HC Wainwright Issues Negative Outlook for SANA Earnings

August 15 at 1:29 AM | americanbankingnews.com

Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price

August 14 at 2:47 PM | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% - Should You Sell?

August 14 at 1:19 PM | marketbeat.com

HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings

August 13, 2026 | marketbeat.com

Analysts Are Bullish on Top Healthcare Stocks: Sana Biotechnology (SANA), Jade Biosciences (JBIO)

August 12, 2026 | theglobeandmail.com

Sana Biotechnology, Inc: Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

August 11, 2026 | finanznachrichten.de

Sana Biotechnology Q2 Adjusted Loss Narrows

August 11, 2026 | finance.yahoo.com

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

August 10, 2026 | markets.businessinsider.com

Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results

August 10, 2026 | marketbeat.com

Sana Biotechnology (SANA) to Release Earnings on Monday

August 9, 2026 | americanbankingnews.com

Sana Biotechnology (SANA) Projected to Release Earnings on Monday

August 3, 2026 | marketbeat.com

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

July 29, 2026 | prnewswire.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 6.8% - Should You Buy?

July 27, 2026 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by Brokerages

July 27, 2026 | marketbeat.com

Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold

July 25, 2026 | seekingalpha.com

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

July 22, 2026 | seekingalpha.com

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

July 20, 2026 | zacks.com

Sana Biotechnology (NASDAQ:SANA) Rating Lowered to "Sell" at Wall Street Zen

July 20, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC, CVAC, OLMA, and SANA Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 08/14/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Olema Pharmaceuticals NASDAQ:OLMA

$10.77 +0.14 (+1.32%)

As of 04:00 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Cartesian Therapeutics NASDAQ:RNAC

$9.18 +0.34 (+3.85%)

As of 04:00 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Sana Biotechnology NASDAQ:SANA

$3.68 +0.13 (+3.66%)

As of 04:00 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAC, CVAC, OLMA, and SANA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAC, CVAC, OLMA, and SANA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAC, CVAC, OLMA, and SANA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC, CVAC, OLMA, and SANA Company Descriptions

CureVac NASDAQ:CVAC

Olema Pharmaceuticals NASDAQ:OLMA

Cartesian Therapeutics NASDAQ:RNAC

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAC, CVAC, OLMA, and SANA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAC, CVAC, OLMA, and SANA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAC, CVAC, OLMA, and SANA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC, CVAC, OLMA, and SANA Company Descriptions

CureVac NASDAQ:CVAC

Olema Pharmaceuticals NASDAQ:OLMA

Cartesian Therapeutics NASDAQ:RNAC

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools